Fahad Butt , Mohamad Tarek Madani , Salem Abu Al-Burak , Thanansayan Dhivagaran , Brendan K. Tao , Amit Garg , Cindy Hutnik , Monali S. Malvankar-Mehta
{"title":"Efficacy and safety of intracameral epinephrine as mydriatic agent in cataract surgery: A systematic review","authors":"Fahad Butt , Mohamad Tarek Madani , Salem Abu Al-Burak , Thanansayan Dhivagaran , Brendan K. Tao , Amit Garg , Cindy Hutnik , Monali S. Malvankar-Mehta","doi":"10.1016/j.jfop.2025.100169","DOIUrl":null,"url":null,"abstract":"<div><h3>Purpose</h3><div>To evaluate the efficacy, safety, and cost implications of using epinephrine (Epi) as an additive in balanced salt solution (BSS) during cataract surgery, focusing on intraoperative pupil dilation, side effects, and cost considerations.</div></div><div><h3>Methods</h3><div>Searches were conducted across multiple databases, including EMBASE, MEDLINE, CINAHL, and Web of Science, up to October 17, 2024. Eligibility criteria included studies assessing intracameral epinephrine for achieving or maintaining mydriasis, and reporting outcomes related to efficacy, adverse effects, intraoperative complications, and cost implications.</div></div><div><h3>Results</h3><div>Of the 476 articles screened, 23 met the inclusion criteria, involving 4262 cataract surgeries were included. Intracameral epinephrine consistently maintained pupil dilation, with reported average pupil sizes ranging from 6.9 mm to 7.2 mm, significantly reducing the need for additional mechanical dilation interventions (reported incidence <1% in some studies). Its use reduced the incidence of intraoperative floppy iris syndrome (IFIS) in high-risk patients. It minimized complications such as posterior capsular rupture and iris prolapse. Combination therapy with adjunctive agents like NSAIDs or lidocaine further improved dilation stability and reduced intraoperative miosis. Safety data revealed no significant impact on heart rate or blood pressure, demonstrating hemodynamic stability. Cost analyses highlighted savings from reduced surgical times (i.e., ∼13.5 min vs. ∼17.2 min with epinephrine alone) and decreased use of pupil expansion devices, resulting in estimated savings of over $19,000 in high-volume centers.</div></div><div><h3>Conclusion</h3><div>Intracameral epinephrine effectively supports stable pupil dilation and reduces intraoperative complications in cataract surgery. It offers a safe and cost-effective alternative to traditional mydriatic agents, particularly when combined with adjunctive medications. However, given the considerable advancements in surgical techniques over time, caution should be exercised when interpreting findings from earlier studies. Additionally, the cost of epinephrine preparation, alongside its potential endothelial toxicity at higher concentrations, highlights the need for further research into the feasibility of using BSS without epinephrine in routine practice.</div></div>","PeriodicalId":100740,"journal":{"name":"JFO Open Ophthalmology","volume":"11 ","pages":"Article 100169"},"PeriodicalIF":0.0000,"publicationDate":"2025-05-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JFO Open Ophthalmology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2949889925000170","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Purpose
To evaluate the efficacy, safety, and cost implications of using epinephrine (Epi) as an additive in balanced salt solution (BSS) during cataract surgery, focusing on intraoperative pupil dilation, side effects, and cost considerations.
Methods
Searches were conducted across multiple databases, including EMBASE, MEDLINE, CINAHL, and Web of Science, up to October 17, 2024. Eligibility criteria included studies assessing intracameral epinephrine for achieving or maintaining mydriasis, and reporting outcomes related to efficacy, adverse effects, intraoperative complications, and cost implications.
Results
Of the 476 articles screened, 23 met the inclusion criteria, involving 4262 cataract surgeries were included. Intracameral epinephrine consistently maintained pupil dilation, with reported average pupil sizes ranging from 6.9 mm to 7.2 mm, significantly reducing the need for additional mechanical dilation interventions (reported incidence <1% in some studies). Its use reduced the incidence of intraoperative floppy iris syndrome (IFIS) in high-risk patients. It minimized complications such as posterior capsular rupture and iris prolapse. Combination therapy with adjunctive agents like NSAIDs or lidocaine further improved dilation stability and reduced intraoperative miosis. Safety data revealed no significant impact on heart rate or blood pressure, demonstrating hemodynamic stability. Cost analyses highlighted savings from reduced surgical times (i.e., ∼13.5 min vs. ∼17.2 min with epinephrine alone) and decreased use of pupil expansion devices, resulting in estimated savings of over $19,000 in high-volume centers.
Conclusion
Intracameral epinephrine effectively supports stable pupil dilation and reduces intraoperative complications in cataract surgery. It offers a safe and cost-effective alternative to traditional mydriatic agents, particularly when combined with adjunctive medications. However, given the considerable advancements in surgical techniques over time, caution should be exercised when interpreting findings from earlier studies. Additionally, the cost of epinephrine preparation, alongside its potential endothelial toxicity at higher concentrations, highlights the need for further research into the feasibility of using BSS without epinephrine in routine practice.
目的评价在白内障手术中使用肾上腺素(Epi)作为平衡盐溶液(BSS)添加剂的疗效、安全性和成本影响,重点关注术中瞳孔扩张、副作用和成本考虑。方法检索截止到2024年10月17日的多个数据库,包括EMBASE、MEDLINE、CINAHL和Web of Science。入选标准包括评估肠胃膜内肾上腺素用于实现或维持滴虫病的研究,并报告与疗效、不良反应、术中并发症和成本相关的结果。结果476篇文献中,23篇符合纳入标准,共纳入4262例白内障手术。内窥镜肾上腺素持续维持瞳孔扩张,报道的平均瞳孔大小在6.9 mm至7.2 mm之间,显著减少了额外机械扩张干预的需要(在一些研究中报道的发生率为1%)。它的使用降低了高危患者术中虹膜松弛综合征(IFIS)的发生率。它减少并发症,如后囊膜破裂和虹膜脱垂。与非甾体抗炎药或利多卡因等辅助药物联合治疗可进一步改善舒张稳定性并减少术中缩小。安全性数据显示对心率或血压无显著影响,表明血流动力学稳定。成本分析强调了减少手术时间(即,与单独使用肾上腺素的17.2分钟相比,减少手术时间为13.5分钟)和减少瞳孔扩张装置的使用所节省的费用,估计在大容量中心节省了超过19,000美元。结论膜内肾上腺素能有效地支持白内障手术中稳定的瞳孔扩张,减少术中并发症。它提供了一种安全且具有成本效益的替代传统药物,特别是当与辅助药物联合使用时。然而,随着时间的推移,鉴于手术技术的长足进步,在解释早期研究的结果时应谨慎行事。此外,肾上腺素制备的成本,以及其在高浓度下潜在的内皮毒性,表明需要进一步研究在常规实践中使用不含肾上腺素的BSS的可行性。